BioNTech’s Strong Oncology Pipeline and COVID-19 Vaccine Performance Earns Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
BioNTech SE: Strong Financial Performance and Promising Future Justify Buy Rating
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...